贝达药业：目前尚无可公示的新药项目立项

Core Viewpoint - Beida Pharmaceutical (300558) is focusing on the development of BTK inhibitors, particularly the drug Oubreti, while also exploring the integration of artificial intelligence (AI) in drug discovery and clinical research [1] Group 1 - Beida Pharmaceutical is currently monitoring developments in the BTK inhibitor field and has no new drug projects publicly announced [1] - The company recognizes the significant potential of AI in areas such as target discovery, resistance mechanism identification, and real-world research [1] - Beida Pharmaceutical plans to actively incorporate AI-assisted technologies to enhance research and development efficiency [1]